Organization (Industry)
TALPHERA, INC.
ClinicalTrials.gov lists TALPHERA, INC. as lead sponsor of 18 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers TALPHERA, INC.: 18 lead-sponsored trials and 1 legal-entity registration.
Disease areas (5)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 9 |
| Postoperative Pain | 6 |
| Acute Kidney Injury | 1 |
| Acute Pain | 1 |
| Anxiety Disorders | 1 |
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2016 | 2 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 6 |
| 2009 | 3 |
| 2008 | 2 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Regional anesthesia and pain medicine | 2 |
| Anesthesiology | 1 |
| Clinical therapeutics | 1 |
| Pain practice : the official journal of World Institute of Pain | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 27 | 0 | 2021-07-13 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | not reported | -14,290,000 | 6,033,000 |
| 2024 | not reported | -13,004,000 | 6,718,000 |
| 2023 | not reported | -18,397,000 | 5,546,000 |
| 2022 | not reported | 47,755,000 | 3,341,000 |
| 2021 | not reported | -35,099,000 | 4,095,000 |
| 2020 | not reported | -40,379,000 | 4,017,000 |
| 2019 | not reported | -53,240,000 | 4,661,000 |
| 2018 | 2,151,000 | -47,149,000 | 13,137,000 |
| 2017 | 7,995,000 | -51,508,000 | 19,409,000 |
| 2016 | 17,357,000 | -43,157,000 | 21,402,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (53)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-25 | Follow-on offering | 5,561,005 | Edgar offerings |
| 2026-03-13 | Private placement | 4,100,000 | Sec extracted |
| 2025-12-02 | Other financing | not disclosed | Edgar offerings |
| 2025-10-21 | Private placement | 1,600,000 | Sec extracted |
| 2025-09-29 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 53 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (98)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-25 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-13 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-02 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-10-21 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-29 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 98 events.
Biomarker capability evidence (5)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ARX | Trial sponsor | Named in trial exclusion criteria |
| ARX | Trial sponsor | Named in trial exclusion criteria |
| ARX | Trial sponsor | Mentioned in trial text |
| ARX | Trial sponsor | Mentioned in trial text |
| CST1 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sponsor delivery record, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.